RLMD Earnings Relmada Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.22 | 2026-05-12 | 10-Q |
| FY 2025 | 2025-12-31 | -1.45 | 2026-03-19 | 10-K |
| Q3 2025 | 2025-09-30 | -1.16 | 2025-11-13 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.86 | 2025-08-07 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.58 | 2026-05-12 | 10-Q |
| FY 2025 | 2024-12-31 | -2.65 | 2026-03-19 | 10-K |
| Q3 2025 | 2024-09-30 | -2.03 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -1.31 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.72 | 2025-05-12 | 10-Q |
| FY 2024 | 2023-12-31 | -3.28 | 2025-03-27 | 10-K |
| Q3 2024 | 2023-09-30 | -2.45 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.72 | 2024-08-07 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.87 | 2024-05-08 | 10-Q |
| FY 2023 | 2022-12-31 | -5.30 | 2024-03-19 | 10-K |
| Q3 2023 | 2022-09-30 | -4.04 | 2023-11-08 | 10-Q |
| Q2 2023 | 2022-06-30 | -2.73 | 2023-08-08 | 10-Q |
| FY 2022 | 2021-12-31 | -7.16 | 2023-03-23 | 10-K |
| Q3 2022 | 2021-09-30 | -5.36 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | -2.90 | 2022-08-11 | 10-Q |
| Q2 2019 | 2018-12-31 | -0.55 | 2019-02-13 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.